Siqing Fu

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Gynecol Oncol 126:47-53. 2012
  2. doi request reprint Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 30:2891-6. 2012
  3. pmc Overcoming platinum resistance through the use of a copper-lowering agent
    Siqing Fu
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 11:1221-5. 2012
  4. ncbi request reprint Targeting Aurora kinases in ovarian cancer
    Siqing Fu
    Department of Gynecologic Medical Oncology, The University of Texas, MD Anderson Cancer Center, PO Box 301439, Houston, Texas 77230 1439, USA
    Expert Opin Ther Targets 10:77-85. 2006
  5. doi request reprint Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 10:1300-7. 2011
  6. doi request reprint Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 29:3547-52. 2011
  7. pmc Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1661-9. 2011
  8. doi request reprint Development of curcumin as an epigenetic agent
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4670-6. 2010
  9. ncbi request reprint Clinical application of oxaliplatin in epithelial ovarian cancer
    S Fu
    Department of Gynecologic Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Int J Gynecol Cancer 16:1717-32. 2006
  10. pmc PIK3CA mutations in advanced cancers: characteristics and outcomes
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 3:1566-75. 2012

Detail Information

Publications57

  1. pmc Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Gynecol Oncol 126:47-53. 2012
    ..On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer...
  2. doi request reprint Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 30:2891-6. 2012
    ..Patients with advanced malignancies referred for early clinical trials have a short life expectancy. We designed this survey to ascertain the status of advance care planning in this population...
  3. pmc Overcoming platinum resistance through the use of a copper-lowering agent
    Siqing Fu
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 11:1221-5. 2012
    ..Evaluation of this novel strategy is warranted in larger studies to assess the efficacy of this approach for treating platinum-resistant advanced epithelial ovarian cancer in patients with high copper levels...
  4. ncbi request reprint Targeting Aurora kinases in ovarian cancer
    Siqing Fu
    Department of Gynecologic Medical Oncology, The University of Texas, MD Anderson Cancer Center, PO Box 301439, Houston, Texas 77230 1439, USA
    Expert Opin Ther Targets 10:77-85. 2006
    ..The authors propose that Aurora kinase inhibitors be developed as molecular therapeutic agents in order to minimise their toxicities and maximise their antitumour activities for ovarian cancer treatment...
  5. doi request reprint Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 10:1300-7. 2011
    ..HAI nab-paclitaxel showed partial hepatic extraction. At doses 260 mg/m(2) or less given for 1 hour every 3 weeks, the treatment was well-tolerated and showed activity in advanced cancer patients with predominant liver metastases...
  6. doi request reprint Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 29:3547-52. 2011
    ..This study assessed outcomes of individuals with advanced cancer who required admission to an intensive care unit (ICU) after referral for an early clinical trial because they did not respond to conventional therapy...
  7. pmc Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1661-9. 2011
    ..A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer...
  8. doi request reprint Development of curcumin as an epigenetic agent
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4670-6. 2010
    ..The development of curcumin as an epigenetic agent warrants further preclinical and clinical studies to explore its diversity and efficacy in cancer treatment and in combination with other anticancer agents...
  9. ncbi request reprint Clinical application of oxaliplatin in epithelial ovarian cancer
    S Fu
    Department of Gynecologic Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Int J Gynecol Cancer 16:1717-32. 2006
    ..This article reviews the current status of the clinical application of oxaliplatin alone and in a combination regimen in epithelial ovarian cancer treatment...
  10. pmc PIK3CA mutations in advanced cancers: characteristics and outcomes
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 3:1566-75. 2012
    ..PIK3CA mutations, especially, H1047R, were associated with attaining a PR/CR to PI3K/AKT/mTOR pathway inhibitors...
  11. pmc Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Texas, USA
    Oncotarget 4:772-84. 2013
    ..We therefore investigated the outcome of EGFR inhibitor-based combination regimens in patients with heavily-pretreated non-small cell lung cancer (NSCLC) referred to a Phase I Clinic...
  12. doi request reprint Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity
    John Moroney
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:5796-805. 2012
    ..Preclinical data suggest that combining the mTOR/hypoxia-inducible factor (HIF) inhibitor temsirolimus and the antiangiogenesis antibody bevacizumab may augment antitumor activity as well as resensitize cells to anthracyclines...
  13. pmc KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e38033. 2012
    ..To evaluate clinicopathologic and molecular features of patients with metastatic colorectal cancer (mCRC) and their outcomes in early-phase trials using pathway-targeting agents...
  14. pmc Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
    Ishwaria M Subbiah
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:153-62. 2013
    ..Patients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease...
  15. pmc Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases
    Luis H Camacho
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Colorectal Cancer 9:311-4. 2010
    ....
  16. doi request reprint Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience
    David S Hong
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Colorectal Cancer 11:297-303. 2012
    ..Patients with advanced colorectal cancer have a poor prognosis once standard therapies fail. This retrospective study presents the characteristics and outcomes in 144 patients treated in phase I clinical trials...
  17. pmc PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:276-84. 2013
    ..6, 95% confidence interval (CI), 1.02-43.0, P = 0.047). Our data suggest that interaction between PIK3CA mutation H1047R versus other aberrations and response to PI3K/AKT/mTOR axis inhibitors warrants further exploration...
  18. doi request reprint Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:6373-83. 2012
    ..We initiated a personalized medicine program in the context of early clinical trials, using targeted agents matched with tumor molecular aberrations. Herein, we report our observations...
  19. doi request reprint Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 71:389-97. 2013
    ..Liver metastases in patients with cancer are associated with poor survival. We hypothesized that hepatic arterial infusion (HAI) of oxaliplatin combination therapy would have antitumor activity in these patients...
  20. doi request reprint Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Biostatistics, and Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:2922-9. 2012
    ....
  21. pmc A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:4086-94. 2010
    ..The authors of this report conducted a phase 1 study of hepatic arterial infusion (HAI) oxaliplatin combination therapy in patients with advanced cancer and liver metastases...
  22. pmc Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 68:247-53. 2011
    ..The survival of patients with liver metastases from solid tumors is poor. We conducted a phase I study of hepatic arterial infusion (HAI) paclitaxel in patients with advanced cancer and predominant liver involvement...
  23. pmc PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
    Filip Janku
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:777-82. 2012
    ..Concomitant mutations in the mitogen-activated protein kinase (MAPK) pathway may mediate resistance...
  24. pmc Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy
    Henrique A Parsons
    Department of Investigational Cancer Therapeutics A Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Nutr Cancer 64:206-17. 2012
    ..171). In conclusion, body composition was not significantly associated with toxicities or survival in our small sample...
  25. pmc PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e22769. 2011
    ..Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis...
  26. pmc P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy
    Rabin Said
    Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:705-14. 2013
    ..Mutations in the p53 gene are amongst the most frequent aberrations seen in human cancer. Our objective was to characterize the clinical characteristics associated with p53 mutation in patients with advanced cancer...
  27. doi request reprint Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:1422-8. 2012
    ....
  28. doi request reprint Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA Electronic address
    Cell Rep 6:377-87. 2014
    ..This work provides further important clinical validation for continued and accelerated use of biomarker-driven trials incorporating rational drug combinations. ..
  29. pmc Mechanistic basis for overcoming platinum resistance using copper chelating agents
    Zheng D Liang
    Department of Molecular Pathology, Unit 951, Room 2SCR4 3025, The University of Texas MD Anderson Cancer Center, 7435 Fannin Blvd, Houston, TX 77054, USA
    Mol Cancer Ther 11:2483-94. 2012
    ..This study reveals the mechanistic basis for using copper chelation to overcome cDDP resistance in clinical investigations...
  30. pmc Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 13:1034-41. 2012
    ..The growth-inhibitory effect was accompanied by reduction in expression of histone 3 and an increase in apoptosis. We conclude that VE 465 enhances the efficacy of carboplatin agents in ovarian carcinoma...
  31. doi request reprint Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis
    Apostolia M Tsimberidou
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Hepatogastroenterology 59:960-4. 2012
    ..We conducted a phase I trial of IP oxaliplatin and paclitaxel with IV paclitaxel and bevacizumab in patients with peritoneal carcinomatosis...
  32. doi request reprint Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis
    Yanfang Li
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Obstet Gynecol 200:177.e1-9. 2009
    ..The objective of the study was to investigate whether azacitidine sensitizes platinum-resistant ovarian cancer cells to carboplatin and the possible mechanisms involved...
  33. doi request reprint Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
    Prasanth Ganesan
    Corresponding Author Filip Janku, Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, FC8 2018, Box 0455, Houston, Texas 77030
    Mol Cancer Ther 12:2857-63. 2013
    ..PIK3CA mutations are associated with simultaneous KRAS mutations, possibly accounting for therapeutic resistance...
  34. pmc Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer
    Gerald S Falchook
    Department of Investigational Cancer Therapeutics Phase I Program, U T MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:118-27. 2013
    ..Preclinical data indicate EGFR signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic in animal models...
  35. pmc Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience
    Hazem El-Osta
    Department of Investigational Therapeutics, Phase 1 Program Unit 455, Division of Cancer Medicine, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Oncologist 16:1292-8. 2011
    ..Research biopsies are crucial for exploring the impact of novel agents on putative targets. The current study assesses the safety and success rate associated with performing such biopsies...
  36. doi request reprint Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations
    Jennifer J Wheler
    Corresponding Author Jennifer Wheler, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Unit 455, 1400 Holcombe Boulevard, Houston, TX 77030
    Mol Cancer Ther 12:2167-75. 2013
    ..This combination warrants further study in select populations of non-small cell lung cancer...
  37. doi request reprint Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit
    Siqing Fu
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncologist 18:1315-20. 2013
    ..We conducted this retrospective study to identify reasons that patients referred to a phase I clinical trial failed to enroll or delayed enrollment onto the trial...
  38. pmc Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies
    Gerald S Falchook
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 31:1192-200. 2013
    ..Clinical correlates included evaluation of epigenetic changes, methylation patterns, and histone acetylation levels in peripheral blood mononuclear cells...
  39. doi request reprint Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:6144-51. 2012
    ..In this study, the authors evaluated the tolerability, pharmacokinetics (PK), and activity of EZN-2208 in adult patients with advanced solid tumors...
  40. doi request reprint Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase 1 Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:5142-50. 2011
    ..Therefore, the concurrent use of complementary and alternative medicine (CAM) in patients with advanced malignancies seen in a dedicated phase 1 clinic was evaluated...
  41. pmc Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 66:1087-93. 2010
    ..We conducted a phase I study of hepatic arterial infusion (HAI) cisplatin and systemic chemotherapy in patients with advanced cancer and dominant liver involvement...
  42. pmc Update on aurora kinase inhibitors in gynecologic malignancies
    Xia Tao
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Recent Pat Anticancer Drug Discov 3:162-77. 2008
    ..In this review, we summarize the most recent advances in preclinical studies and clinical trials of patented Aurora kinase inhibitors for gynecologic tumors...
  43. pmc PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, FC8 2057, Box 0455, Houston, TX 77030, USA
    Mol Cancer Ther 10:558-65. 2011
    ..5% of patients with diverse solid tumors. The response rate was significantly higher for patients with PIK3CA mutations treated with PI3K/AKT/mTOR pathway inhibitors than for those without documented mutations...
  44. doi request reprint Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
    Aung Naing
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 32:154-9. 2014
    ..Conclusions In summary, the combination of TAS-106 and carboplatin was well-tolerated, and further studies in non-small cell lung and ovarian cancer are warranted to assess the efficacy of this drug combination. ..
  45. doi request reprint Retreatment after secondary resistance or mixed response: a pilot study
    Aung Naing
    The University of Texas, MD Anderson Cancer Center, Houston, Tex
    Oncology 85:350-5. 2013
    ..Here, we report our findings in a pilot study in patients rechallenged with agents previously producing prolonged stable disease (SD), partial or complete remission (PR/CR) or a mixed response, followed by progression...
  46. pmc Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy
    Macus Tien Kuo
    Department of Molecular Pathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77054, USA
    Cancer Res 72:4616-21. 2012
    ....
  47. doi request reprint Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, University of Texas M D Anderson Cancer Center, 1515Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 16:4031-7. 2010
    ....
  48. doi request reprint Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer
    Hong Zheng
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Am J Obstet Gynecol 201:367.e1-6. 2009
    ..To investigate the role of cyclin G1 and cyclin B1 in ovarian tumorigenesis...
  49. pmc Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications
    Yunyun Jiang
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:884-9. 2013
    ..Our pilot data suggest that PTPRD germline mutations may play a role in the development of Ewing sarcoma, a disease of young people, and their presence may have implications for therapy. ..
  50. doi request reprint Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest
    Hong Zheng
    Department of Gynecologic Oncology, Unit 1362, The University of Texas M D Anderson Cancer Center, 1155 Pressler Street, Houston, Texas 77030, USA
    Pharm Res 25:2272-82. 2008
    ..DDAP improves platinum solubility which may reduce systemic toxicity and be more efficacious than cisplatin in killing tumor cells...
  51. doi request reprint Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial
    Ana M Gonzalez-Angulo
    Authors Affiliations Departments of Breast Medical Oncology and Systems Biology, Surgical Oncology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas Sarcoma Oncology Center, Santa Monica Division of Hematology Oncology, University of California, San Diego, California and Celgene, Summit, New Jersey
    Clin Cancer Res 19:5474-84. 2013
    ..This dose-finding phase I study investigated the maximum-tolerated dose (MTD) and safety of weekly nanoparticle albumin-bound rapamycin (nab-rapamycin) in patients with untreatable advanced nonhematologic malignancies...
  52. pmc Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:2625-31. 2012
    ..Temsirolimus was combined with cixutumumab, a fully human IgG1 monoclonal antibody directed at the insulin growth factor-1 receptor (IGF-1R)...
  53. pmc The changing face of phase 1 cancer clinical trials: new challenges in study requirements
    Barbara S Craft
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:1592-7. 2009
    ..Although both phase 1 and phase 2 trials had substantial study requirements, those for the phase 1 studies were significantly higher. The successful conduct of early-phase clinical trials requires significant research infrastructure...
  54. ncbi request reprint What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
    X Cheng
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Chemother 21:566-72. 2009
    ..Seventeen (26.6%) patients had improved performance status scores. Bevacizumab combined with chemotherapy showed promising clinical benefits, with significant response of serum CA125 concentration and moderate adverse effects...
  55. ncbi request reprint Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction
    Yanfang Li
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, 1155 Pressler Street, Houston, TX 77030, USA
    Gynecol Oncol 106:375-80. 2007
    ..We sought to investigate the toxicity and efficacy of PLD in gynecologic cancer patients with CKD...
  56. ncbi request reprint Hormonal therapy in ovarian cancer
    H Zheng
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Int J Gynecol Cancer 17:325-38. 2007
    ..Molecular markers that can reliably predict major clinical outcomes should be investigated further in well-designed trials...
  57. ncbi request reprint Systemic anticancer therapy in gynecological cancer patients with renal dysfunction
    Y F Li
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Int J Gynecol Cancer 17:739-63. 2007
    ..We also review the formulae commonly used to estimate creatinine clearance, including Cockcroft-Gault, Chatelut, Jelliffe, Wright, and the Modification of Diet in Renal Disease study formulae...